Search Results - hmgn1

2 Results

Sort By:

Therapeutic Antitumor Combination Containing TLR4 Agonist HMGN1

Abstract: Immune checkpoint inhibitors (e.g. CTLA-4, PD-L1) have recently shown significant promise in the treatment of cancer. However, when used alone, these checkpoint inhibitors are limited by the absence or repression of immune cells within the targeted cancer. For those cancers associated with these limited immune systems, there remains a need...

Published: 5/22/2024 | Inventor(s): Joost Oppenheim, De Yang, Michael Bustin

Keywords(s): Alarmin, Checkpoint Inhibitor, CTLA-4, HMGN1, Immunooncology, Oppenheim, TLR4, TLR7/8

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics

Immunotherapy Combination Treatment Containing both TLR4 and TLR2/6 Agonists, a Checkpoint Inhibitor, and a STING agonist.

Abstract: Melanoma is an aggressive form of skin cancer that commonly becomes metastatic, spreading to nearby tissue or other parts of the body, including distant skin or subcutaneous sites such as the lungs, liver, brain, or bone. Metastatic melanoma is very drug resistant and difficult to treat, and therefore, the prognosis for these patients is poor....

Published: 5/22/2024 | Inventor(s): Md Alam, De Yang, Joost Oppenheim

Keywords(s): cGAMP, Combination Therapy, FSL-1, HMGN1, Immune Checkpoint Inhibitor, Immunotherapy, Melanin-Producing Melanoma, MELANOMA, Oppenheim, RESISTANT, STING Agonist, TLR, TLR2/6, TLR4, TLR4 Agonist, Toll-like receptor, TRL2/6 Agonist

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration